Un estudio de LY4515100 en participantes sanos
Un estudio de Fase 1, aleatorizado, cegado para el investigador y el participante, controlado con placebo, de dosis única y múltiple ascendente para caracterizar la seguridad, tolerabilidad y farmacocinética de LY4515100 en participantes sanos
The main purpose of this study is to assess the safety and tolerability of LY4515100 when given orally to healthy participants. LY4515100 will be given by itself or with other medicines. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will have 3 parts and will last about 50 days. For each participant in Part A, the study will include a stay in the Clinical Research Unit (CRU) lasting about 6 days. For each participant in Part B, the study will include a stay in the CRU lasting about 15 days. For each participant in Part C, the study will include up to 2 stays in the CRU each lasting between 7-28 days.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase 1
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
- Número de teléfono: 1-317-615-4559
- Correo electrónico: LillyTrials@Lilly.com
Copia de seguridad de contactos de estudio
- Nombre: Physicians interested in becoming principal investigators please contact
- Correo electrónico: clinical_inquiry_hub@lilly.com
Ubicaciones de estudio
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75247
- Reclutamiento
- Fortrea Clinical Research Unit
-
Investigador principal:
- Gene Voskuhl
-
Contacto:
- Número de teléfono: 866-429-3700
-
-
Wisconsin
-
Madison, Wisconsin, Estados Unidos, 53704
- Reclutamiento
- Fortrea Clinical Research Unit
-
Investigador principal:
- Kimberly Cruz
-
Contacto:
- Número de teléfono: 866-429-3700
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs, and cardiac monitoring.
-
Have a body mass index (BMI) within the range of 18.5 to 32.0 kilograms per square meter (kg/m²) (inclusive).
-
Individuals not of childbearing potential (INOCBP) may participate in this trial.
-
Participants in the Combined Oral Contraceptive Arm of Part C only:
- must be 18 to 45 years of age (inclusive).
- have a BMI within the range of 18.5 to 30 kg/m².
- may be healthy pre-menopausal assigned female at birth (AFAB) individuals of child bearing potential (IOCBP).
Exclusion Criteria:
-
Have donated 500 milliliters (mL) of blood within 30 days prior to dosing.
-
Have participated within the last 30 days in a clinical study involving an investigational medicinal product. If the previous investigational product (IP) has a long half-life, 5 half-lives or 30 days (whichever is longer) should have passed.
-
Participants with hemoglobin outside of the local laboratory normal reference range for age and sex, which is judged to be clinically significant by the investigator.
-
Participants with an estimated glomerular filtration rate less than (<) 90 milliliter per minute per 1.73 square meters (mL/min/1.73 m²).
-
Have a 12-lead Electrocardiogram (ECG) abnormality that, in the opinion of the investigator,
-
increases the risks associated with participating in the study
-
may confound ECG data analysis
-
Have used or intend to use over-the-counter or prescription medication including dietary or herbal medications within 7 days, or 14 days if the medication is a potential enzyme inducer, or 5 half-lives (whichever is longer), prior to dosing.
-
Smoke more than 10 cigarettes per day or the equivalent, including electronic cigarettes, and are unable to abide by investigative site smoking restrictions.
-
Have an average weekly alcohol intake that exceeds 14 units per week (males 65 years of age or younger) and 7 units per week (females and males greater than 65 years of age, if applicable)
-
Show evidence of
-
Human immunodeficiency virus (HIV) infection and/or positive human HIV antigen and/or antibodies
-
hepatitis C and/or positive hepatitis C antibody
-
hepatitis B and/or positive hepatitis B surface antigen.
-
Have liver disease.
-
Any clinical condition or procedure (for example, gastrointestinal obstruction, gastric bypass, or cholecystectomy) that may affect the absorption, distribution, or excretion of the study drug and confound pharmacokinetics (PK) assessment.
-
Part C Only:
- Have history of neuropathy of any cause.
- Have impaired hearing or a history of hearing problems.
- Have any medical conditions, medical history, or are taking any medications that are contraindicated in the itraconazole prescribing information, such as prior history of hypersensitivity to itraconazole or other azoles.
- Participants with any known history of thyroid disease
-
Participants in the Combined Oral Contraceptive Arm of Part C only:
- Are current smokers or have used nicotine, including tobacco or nicotine replacement products within 14 days prior to the first dose of combined oral contraceptive (COC), or plan to use nicotine, including tobacco or nicotine replacement products during the study.
- Are at high risk for arterial or venous thrombotic diseases, autoimmune disease with lupus anticoagulants or anti-phospholipid syndrome, major surgery within the past 3 months, anticipated prolonged immobility.
- Have abnormalities indicative of increased risk of VTE on the thrombophilia panel at screening.
- Have undiagnosed abnormal uterine bleeding.
- Have any history of breast, uterine or ovarian cancer.
- Use of Vitamin C (greater than or equal to (≥) 500 mg/day) or acetaminophen within 14 days before dosing.
- Have contraindications for the use of levonorgestrel/ethinyl estradiol.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Ciencia básica
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: LY4515100 of Part A (SAD)
Single-ascending doses of LY4515100 will be given orally |
given orally |
|
Experimental: LY4515100 of Part B (MAD)
Multiple-ascending doses of LY4515100 will be given orally |
given orally |
|
Experimental: LY4515100 and Itraconazole of Part C
LY4515100 and Itraconazole will be given orally |
given orally given orally |
|
Experimental: LY4515100 and Metformin of Part C
LY4515100 and Metformin will be given orally |
given orally given orally |
|
Experimental: LY4515100 and Transporter Substrates or Renal Marker of Part C
LY4515100 and Transporter Substrates or Renal Marker will be given either orally or intravenously (IV) |
given orally given orally given orally given IV given orally |
|
Experimental: LY4515100 and Midazolam of Part C
LY4515100 will be given orally. Midazolam will be given orally and IV. |
given orally given orally given IV |
|
Experimental: LY4515100 and Combined Oral Contraceptive of Part C
LY4515100, Levonorgestrel, and Ethinyl Estradiol will be given orally |
given orally given orally given orally |
|
Comparador de placebos: Placebo Part A
Placebo will be given orally |
given orally |
|
Comparador de placebos: Placebo Part B
Placebo will be given orally |
given orally |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of participants with one or more serious adverse event(s) (SAEs) of LY4515100 in Parts A and B
Periodo de tiempo: Day 1 up to Day 30
|
SAEs of LY4515100 |
Day 1 up to Day 30
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
PK: Geometric Means of Area Under the Concentration-Time Curve From 0 to Infinity [AUC(0-∞)] of LY4515100 in Combination with Itraconazole versus LY4515100 Alone
Periodo de tiempo: Day 1 through Day 50
|
Day 1 through Day 50
|
|
|
PK: Geometric Means of Cmax of LY4515100 in Combination with Itraconazole versus LY4515100 Alone
Periodo de tiempo: Day 1 through Day 50
|
Day 1 through Day 50
|
|
|
PK: Geometric Means of AUC(0-∞) of Substrate in Combination with LY4515100 versus Substrate Alone
Periodo de tiempo: Day 1 through Day 36
|
Day 1 through Day 36
|
|
|
PK: Geometric Means of Cmax of Substrate in Combination with LY4515100 versus Substrate Alone
Periodo de tiempo: Day 1 through Day 36
|
Day 1 through Day 36
|
|
|
Pharmacokinetics (PK): Area Under the Concentration versus Time Curve (AUC) of LY4515100
Periodo de tiempo: Day 1 through Day 11
|
PK: AUC of LY4515100 |
Day 1 through Day 11
|
|
PK: Maximum Observed Drug Concentration (Cmax) of LY4515100
Periodo de tiempo: Day 1 through Day 11
|
PK: Cmax of LY4515100 |
Day 1 through Day 11
|
|
PK: Time of maximum observed drug concentration (tmax) of LY4515100
Periodo de tiempo: Day 1 through Day 11
|
PK: tmax of LY4515100 |
Day 1 through Day 11
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Director de estudio: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Hormonas
- Hormonas, sustitutos hormonales y antagonistas hormonales
- Compuestos de azufre
- Químicos orgánicos
- Compuestos heterocíclicos, 1 anillo
- Compuestos heterocíclicos
- Compuestos heterocíclicos, 2 anillos
- Compuestos heterocíclicos, anillo fusionado
- Azoles
- Hidrocarburos
- Hidrocarburos, cíclico
- Carbohidratos
- Ácidos carboxílicos
- Alcaloides
- Hidrocarburos, aromáticos
- Compuestos policíclicos
- Glucósidos
- Amidas
- Purinones
- Purinas
- Pirimidinas
- Esteroides
- Compuestos de anillo fusionado
- Derivados de benceno
- Hidrocarburos, halogenados
- Benzazepines
- Congéneres de estradiol
- Hormonas esteroides gonadal
- Hormonas gonadales
- Biguanides
- Guanidinas
- Amidinos
- Ácidos, carbocíclicos
- Sulfonamidas
- Sulfonas
- Benzoates
- Benzodiacepinas
- Triazoles
- Fluorobencenos
- Hidrocarburos, fluorado
- Piperazines
- Norpregnenes
- Norpregnanos
- Norsteroides
- Xantino
- Ácidos triodobenzoicos
- Yodobenzoates
- Glicosidos Digitalis
- Cardenólidos
- Glucósidos cardíacos
- Cardanólidos
- Norpregnatrienes
- Esteroides estrogénicos, alquilado
- Norgestrel
- Rosuvastatina Cálcica
- Midazolam
- Digoxina
- Metformina
- Cafeína
- Itraconazol
- Levonorgestrel
- Etinilestradiol
- Iohexol
Otros números de identificación del estudio
Otros números de identificación del estudio
- 27789
- J6V-MC-OIAB (Otro identificador: Eli Lilly and Company)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .